Driving Value Creation and Risk-Balanced R&D Productivity through Operational Excellence and Asset Development Strategy
August 8-9, 2017
- Cambridge, MA
CBI’s Bio/Pharma Strategic Portfolio Management Summit — Driving Value Creation and Risk-Balanced R&D Productivity through Operational Excellence and Asset Development Strategy — is a brand new forum offering Bio/Pharma Senior Portfolio Management Executives the opportunity to engage in a candid, interactive discussion on the future direction of portfolio management strategy and its impact on R&D productivity.
The Biopharmaceutical Strategic Portfolio Management Summit promises a highly interactive exchange and solutions oriented discussion on what it really takes to propel value creation.
Address Current Trends and Obstacles Impeding Portfolio Management Performance and Learn How to:
- Address R&D productivity challenges through portfolio diversification — Determine which and how many therapeutic areas to focus on and what mix of early versus late stage projects
- Deploy effective strategies to source innovation and structure R&D organizations
- Achieve a balanced portfolio — Identify and manage risks
- Achieve real-time portfolio prioritization and faster decisions — Preserve an innovative culture while implementing a “fit for purpose” portfolio process
- Determine the best investment in internal and external resources to get your portfolio across the finish line
- Achieve realistic forecasting — Proven models and approaches for resource capacity management
- Create more value with your current resources, assets and IP
- Partner strategically to share cost and risk, access enhanced development capabilities
